ExploreWatchlistsPricing
  1. JP-listed companies
  2. Daito Pharmaceutical Co., Ltd.
  3. Financials
  4. Total liabilities

Daito Pharmaceutical Co., Ltd. (4577)

Market cap
¥41.1B
P/E ratio
16.2x
Daito manufactures active pharmaceutical ingredients and prescription drugs for domestic and international pharmaceutical companies. The company offers an integrated production system from raw materials to final formulations.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal liabilities (Million JPY)YoY (%)
May 31, 202525,936+1.94%
May 31, 202425,443+29.94%
May 31, 202319,580+13.41%
May 31, 202217,265+9.12%
May 31, 202115,822-8.97%
May 31, 202017,381+12.87%
May 31, 201915,400-17.65%
May 31, 201818,701-6.00%
May 31, 201719,894+0.58%
May 31, 201619,780-3.28%
May 31, 201520,451

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat